Back to News
Market Impact: 0.2
Lake Street Initiates Coverage of Spruce Biosciences at Buy
Source: Nasdaq
Healthcare & BiotechAnalyst Insights
Lake Street initiated coverage of Spruce Biosciences (NASDAQCM: SPRB) on September 17, 2026, with a Buy recommendation. The positive analyst initiation highlights investor interest in Spruce's late-stage rare-endocrine therapy pipeline, though the article provides no price target, financial estimates, or clinical-catalyst details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
SPRB0.45
More News
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- Reliance’s Record $19 Billion Surge Lifts Nifty, Keeps India Bulls in the Game
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- Apple reports after the bell. Options traders expect a big move
- Mizuho lowers Lumentum stock price target on Marvell acquisition
- Etsy CMO Bradley Minor sells $410,314 in company stock